SCHEMBL10050008

SCHEMBL10050008

CCc1ccc(-c2ccc(C)cc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.57
KDM4E B2RXH2 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
CYP2C19 P33261 3/20 0.57
CYP1A2 P05177 2/20 0.57
DDAH1 O94760 1/20 0.57
ALOX5 P09917 1/20 0.51
PTGS1 P23219 1/20 0.51
PTGS2 P35354 1/20 0.51
MAPT P10636 7/20 0.45
HPGD P15428 3/20 0.45
CYP2C9 P11712 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CYP2E1 P05181 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2B6 P20813 1/20 0.42
PKM P14618 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19568041 0.83 ALOX5 (0.51) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL2056342 0.82 ALDH1A1 (0.62) ALDH1A1KDM4ESMN1; SMN2CYP2C19ALOX5
SCHEMBL9538809 0.82 ALDH1A1 (0.62) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL9970929 0.82 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL805141 0.81 CYP2C19 (0.64) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL4343079 0.79 NQO2 (0.53) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL805155 0.79 ALDH1A1 (0.60) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL14541695 0.77 NQO2 (0.52) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL20782208 0.76 ALOX5 (0.45) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2
SCHEMBL20621396 0.75 MAPT (0.81) ALDH1A1KDM4ESMN1; SMN2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178749-A1 NS1 PROTEIN INHIBITORS ROTH MICHAEL (US) 2012-07-12 US disclosed
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CORNERSTONE THERAPEUTICS, INC. (US) 2012-03-22 US disclosed
US-8119656-B2 Inhibitors of the influenza virus non-structural 1 protein THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-21 US disclosed
US-7943622-B2 Piperazines, pharmaceutical compositions and methods of use thereof CORNERSTONE THERAPEUTICS, INC. (US) 2011-05-17 US disclosed
US-20090170840-A1 NS1 protein inhibitors THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-07-02 US disclosed
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170840-A1 NS1 protein inhibitors MAVS, SERPINB1, SPINT2 ALDH1A1 3348/4885KDM4E 2872/4885SMN1; SMN2 2775/4885
US-20120071652-A1 Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885KDM4E 3410/4885SMN1; SMN2 782/4885
US-20120178749-A1 NS1 PROTEIN INHIBITORS MAVS, SERPINB1, SPINT2 ALDH1A1 3348/4885KDM4E 2872/4885SMN1; SMN2 2775/4885
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA5, CHRNA2 ALDH1A1 1032/4885KDM4E 3410/4885SMN1; SMN2 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.